These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15777218)

  • 1. Development of prodrugs for enzyme-mediated, tumor-selective therapy.
    Yoon KJ; Potter PM; Danks MK
    Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):107-13. PubMed ID: 15777218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Wallace PM; Senter PD
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme-catalyzed activation of anticancer prodrugs.
    Rooseboom M; Commandeur JN; Vermeulen NP
    Pharmacol Rev; 2004 Mar; 56(1):53-102. PubMed ID: 15001663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prodrug applications for targeted cancer therapy.
    Giang I; Boland EL; Poon GM
    AAPS J; 2014 Sep; 16(5):899-913. PubMed ID: 25004822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
    Tietze LF; Schmuck K
    Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Trends in
    Sun IC; Yoon HY; Lim DK; Kim K
    Bioconjug Chem; 2020 Apr; 31(4):1012-1024. PubMed ID: 32163277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective activation of anthracycline prodrugs for use in conjunction with ADEPT.
    HariKrishna D; Rao AR; Krishna DR
    Drug News Perspect; 2003 Jun; 16(5):309-18. PubMed ID: 12942162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteases as activators for cytotoxic prodrugs in antitumor therapy.
    Weidle UH; Tiefenthaler G; Georges G
    Cancer Genomics Proteomics; 2014; 11(2):67-79. PubMed ID: 24709544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.
    Legigan T; Clarhaut J; Tranoy-Opalinski I; Monvoisin A; Renoux B; Thomas M; Le Pape A; Lerondel S; Papot S
    Angew Chem Int Ed Engl; 2012 Nov; 51(46):11606-10. PubMed ID: 22996951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An activatable prodrug for the treatment of metastatic tumors.
    Kim EJ; Bhuniya S; Lee H; Kim HM; Cheong C; Maiti S; Hong KS; Kim JS
    J Am Chem Soc; 2014 Oct; 136(39):13888-94. PubMed ID: 25238144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prodrugs in photodynamic anticancer therapy.
    Musiol R; Serda M; Polanski J
    Curr Pharm Des; 2011; 17(32):3548-59. PubMed ID: 22074426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates.
    Huennekens FM
    Trends Biotechnol; 1994 Jun; 12(6):234-9. PubMed ID: 7765070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prodrugs in medicinal chemistry and enzyme prodrug therapies.
    Walther R; Rautio J; Zelikin AN
    Adv Drug Deliv Rev; 2017 Sep; 118():65-77. PubMed ID: 28676386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prodrug strategies in cancer therapy.
    Denny WA
    Eur J Med Chem; 2001; 36(7-8):577-95. PubMed ID: 11600229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-specific activation of prodrugs: is there a role for nuclear medicine?
    Antunes IF; Haisma HJ; de Vries EF
    Nucl Med Commun; 2008 Oct; 29(10):845-6. PubMed ID: 18769302
    [No Abstract]   [Full Text] [Related]  

  • 19. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy.
    Senter PD
    FASEB J; 1990 Feb; 4(2):188-93. PubMed ID: 2404820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism-based anticancer drug design.
    Kwon CH
    Arch Pharm Res; 1999 Dec; 22(6):533-41. PubMed ID: 10615856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.